Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Xavier Rebillard

Showing results (51-60 of 65) with videos related to

Pageof 7
Sort By:
BMC Cancer|April 18, 2015
Abiraterone acetate in patients with metastatic castration-resistant prostate cancer: long term outcome of the Temporary Authorization for Use programme in FranceNadine Houédé, Philippe Beuzeboc, Sophie Gourgou, et al.
European Urology Open Science|December 22, 2021
Intervention-related Deaths in the European Randomized Study of Screening for Prostate CancerRebecka Arnsrud Godtman, Sebastiaan Remmers, Gunnar Aus, et al.
Annales De Biologie Clinique|April 1, 2016
[The level of evidence for the use of biomarkers in the early detection of prostate cancer]Pierre-Jean Lamy, Anne-Sophie Gauchez, Laurent Salomon, et al.
European Urology|March 21, 2015
Metastatic Prostate Cancer Incidence and Prostate-specific Antigen Testing: New Insights from the European Randomized Study of Screening for Prostate CancerCarlotta Buzzoni, Anssi Auvinen, Monique J Roobol, et al.
European Urology|April 23, 2023
Relationship Between Baseline Prostate-specific Antigen on Cancer Detection and Prostate Cancer Death: Long-term Follow-up from the European Randomized Study of Screening for Prostate CancerSebastiaan Remmers, Chris H Bangma, Rebecka A Godtman, et al.
BMJ Open|December 21, 2023
Cohort profile: COBLAnCE: a French prospective cohort to study prognostic and predictive factors in bladder cancer and to generate real-world data on treatment patterns, resource use and quality of lifeThierry Lebret, Julia Bonastre, Aldéric Fraslin, et al.
World Journal of Urology|November 26, 2013
Clinical outcomes after salvage radiotherapy without androgen deprivation therapy in patients with persistently detectable PSA after radical prostatectomy: results from a national multicentre studyGuillaume Ploussard, Frédéric Staerman, Jean Pierrevelcin, et al.
The New England Journal of Medicine|March 20, 2009
Screening and prostate-cancer mortality in a randomized European studyFritz H Schröder, Jonas Hugosson, Monique J Roobol, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|May 11, 2007
[The prostate: how to treat this symbol of male vulnerability? An Association Française d'Urologie (AFU)-IPSOS qualitative survey]Bardon Yves, Alexandre de la Taille, Emmanuel Chartier-Kastler, et al.
European Urology|August 8, 2009
Prostate cancer mortality reduction by prostate-specific antigen-based screening adjusted for nonattendance and contamination in the European Randomised Study of Screening for Prostate Cancer (ERSPC)Monique J Roobol, Melissa Kerkhof, Fritz H Schröder, et al.
Pageof 7

Showing results (51-60 of 65) with videos related to

Sort By:
Pageof 7
BMC Cancer|April 18, 2015
Abiraterone acetate in patients with metastatic castration-resistant prostate cancer: long term outcome of the Temporary Authorization for Use programme in FranceNadine Houédé, Philippe Beuzeboc, Sophie Gourgou, et al.
European Urology Open Science|December 22, 2021
Intervention-related Deaths in the European Randomized Study of Screening for Prostate CancerRebecka Arnsrud Godtman, Sebastiaan Remmers, Gunnar Aus, et al.
Annales De Biologie Clinique|April 1, 2016
[The level of evidence for the use of biomarkers in the early detection of prostate cancer]Pierre-Jean Lamy, Anne-Sophie Gauchez, Laurent Salomon, et al.
European Urology|March 21, 2015
Metastatic Prostate Cancer Incidence and Prostate-specific Antigen Testing: New Insights from the European Randomized Study of Screening for Prostate CancerCarlotta Buzzoni, Anssi Auvinen, Monique J Roobol, et al.
European Urology|April 23, 2023
Relationship Between Baseline Prostate-specific Antigen on Cancer Detection and Prostate Cancer Death: Long-term Follow-up from the European Randomized Study of Screening for Prostate CancerSebastiaan Remmers, Chris H Bangma, Rebecka A Godtman, et al.
BMJ Open|December 21, 2023
Cohort profile: COBLAnCE: a French prospective cohort to study prognostic and predictive factors in bladder cancer and to generate real-world data on treatment patterns, resource use and quality of lifeThierry Lebret, Julia Bonastre, Aldéric Fraslin, et al.
World Journal of Urology|November 26, 2013
Clinical outcomes after salvage radiotherapy without androgen deprivation therapy in patients with persistently detectable PSA after radical prostatectomy: results from a national multicentre studyGuillaume Ploussard, Frédéric Staerman, Jean Pierrevelcin, et al.
The New England Journal of Medicine|March 20, 2009
Screening and prostate-cancer mortality in a randomized European studyFritz H Schröder, Jonas Hugosson, Monique J Roobol, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|May 11, 2007
[The prostate: how to treat this symbol of male vulnerability? An Association Française d'Urologie (AFU)-IPSOS qualitative survey]Bardon Yves, Alexandre de la Taille, Emmanuel Chartier-Kastler, et al.
European Urology|August 8, 2009
Prostate cancer mortality reduction by prostate-specific antigen-based screening adjusted for nonattendance and contamination in the European Randomised Study of Screening for Prostate Cancer (ERSPC)Monique J Roobol, Melissa Kerkhof, Fritz H Schröder, et al.
Pageof 7